Novel agents for anti-platelet therapy.
Novel agents for anti-platelet therapy.
复制标题
抗血小板治疗的新型药物
DOI：
10.1186/1756-8722-4-44
复制
发表时间：
2011-11-04
影响因子：
28.5
通讯作者：
Hou M
中科院分区：
文献类型：
--
作者：
Ji X;Hou M
抗血小板治疗在血栓性疾病患者的治疗中发挥着重要作用。最常用的抗血小板药物是阿司匹林、噻氯匹定、氯吡格雷，对预防和治疗心脑血管疾病有效。糖蛋白 IIb/IIIa 拮抗剂（例如阿昔单抗、依替巴肽和替罗非班）在减少急性冠脉综合征缺血事件方面已表现出良好的临床效益和安全性。然而，在使用糖蛋白 IIb/IIIa 拮抗剂治疗的病例中，已有与血栓形成或出血相关的不良事件的报告。西洛他唑是一种抗血小板药物，用于治疗外周缺血（例如间歇性跛行）的患者。目前，血小板二磷酸腺苷 P2Y(12) 受体拮抗剂（例如氯吡格雷、普拉格雷、坎格雷洛和替格瑞洛）因其显着的保护作用而被用于临床。新型蛋白酶激活受体拮抗剂 vorapaxar 和 atopaxar 可能会降低缺血事件的风险，而不会显着增加出血率。其他一些正在进行临床试验的抗血小板新药也已推出。事实上，新型抗血小板药物的数量正在增加。因此，这些抗血小板药物在实际患者中的疗效值得仔细研究，特别是在出血风险方面。希望能够开发出具有高抗血栓效率和低出血副作用的新型选择性血小板抑制剂。
Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and treatment of cardio-cerebrovascular diseases. Glycoprotein IIb/IIIa antagonists (e.g., abciximab, eptifibatide and tirofiban) have demonstrated good clinical benefits and safety profiles in decreasing ischemic events in acute coronary syndrome. However, adverse events related to thrombosis or bleeding have been reported in cases of therapy with glycoprotein IIb/IIIa antagonists. Cilostazol is an anti-platelet agent used in the treatment of patients with peripheral ischemia, such as intermittent claudication. Presently, platelet adenosine diphosphate P2Y(12) receptor antagonists (e.g., clopidogrel, prasugrel, cangrelor, and ticagrelor) are being used in clinical settings for their pronounced protective effects. The new protease-activated receptor antagonists, vorapaxar and atopaxar, potentially decrease the risk of ischemic events without significantly increasing the rate of bleeding. Some other new anti-platelet drugs undergoing clinical trials have also been introduced. Indeed, the number of new anti-platelet drugs is increasing. Consequently, the efficacy of these anti-platelet agents in actual patients warrants scrutiny, especially in terms of the hemorrhagic risks. Hopefully, new selective platelet inhibitors with high anti-thrombotic efficiencies and low hemorrhagic side effects can be developed.
登录
查看更多内容
影响因子：
5
作者：
Kogushi, Motoji;Matsuoka, Toshiyuki;Hishinuma, Ieharu
通讯作者：
Hishinuma, Ieharu
影响因子：
5
作者：
Kogushi, Motoji;Matsuoka, Toshiyuki;Hishinuma, Ieharu
通讯作者：
Hishinuma, Ieharu
影响因子：
6.7
作者：
Iyu, David;Glenn, Jackie R.;Heptinstall, Stan
通讯作者：
Heptinstall, Stan
影响因子：
37.8
作者：
James, Stefan;Budaj, Andrzej;Wallentin, Lars
通讯作者：
Wallentin, Lars
DOI：
10.1016/b978-0-12-385526-8.00013-8
发表时间：
2011-01-01
期刊：
PHARMACOLOGY OF PURINE AND PYRIMIDINE RECEPTORS
影响因子：
--
作者：
Erlinge, David
通讯作者：
Erlinge, David